I-Corps Teams: Development of Noninvasive Diabetes Breath Sensors

该I-Corps项目的更广泛的影响/商业潜力，使非侵入性，简单和便携式监测人体呼吸的血糖水平。该项目将为研究生提供商业化培训，并加强学生对商业化技能的学习。作为一个潜在的社会影响，这项创新将提高生活质量，通过使用非侵入性呼吸传感器识别糖尿病患者的人体血糖水平。新的发现将通过演示、研讨会、合作伙伴关系和潜在的技术转让给初创公司来传播。来自不同公司的工业合作者将帮助将这一创新转化为工程实践。I-Corps的项目是为一种非侵入式呼吸生物传感器的商业化进行市场分析和客户访谈，这种生物传感器可以检测呼出气体中的丙酮，从而识别人体血糖水平。分子印迹层通过允许特定分子暴露到传感器中来提高传感器的选择性。丙酮印迹传感器在0-10 ppm的范围内与丙酮浓度的增长呈宽范围的线性关系，灵敏度约为15/ppm。与市场上现有的糖尿病传感器相比，该传感器具有以下优点。该传感器对0.9 ppm至10 ppm的丙酮具有线性气体响应，这导致准确检测糖尿病患者呼吸中的丙酮浓度（通常在1.7 ppm至3.7 ppm的范围内）。该传感器表现出高稳定性，改进的选择性，并从不同的气体分子，如水分，乙醇等丙酮的高灵敏度。该传感器具有小尺寸，可以装在口袋里。糖尿病患者可以方便、离散地携带传感器，实时检测呼出气中的丙酮，识别人体血糖水平，帮助确定患者？该奖项反映了NSF的法定使命，并被认为是值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估的支持。

The broader impact/commercial potential of this I-Corps project to enable a non-invasive, simple and portable monitoring blood glucose levels from human breath. This project will provide the commercialization training to graduate students and enhance students learning on commercialization skills. As a potential societal impact, this innovation will enhance the quality of life, by using noninvasive breath sensors for the recognition of human blood glucose level for diabetics. New discoveries will be disseminated through presentations, workshops, partnerships, and potential technology transfer to a start-up company. Industrial collaborators from various companies will help translate this innovation into engineering practice. More than 100 people will be outreached about the innovations in the noninvasive diabetes sensors during the interview process.This I-Corps project is to conduct market analysis and customer interviews for commercializing a noninvasive breath biosensor for detecting acetone in exhaled breath for the recognition of human blood glucose level. The molecular imprinted layer improved the selectivity of the sensors by allowing the specific molecule to be exposed into the sensor. The acetone-imprinted sensor shows a wide range of linear relationship with the growth of the acetone concentrations in the range of 0-10 ppm at a sensitivity about 15 Ω/ppm. This sensor has the following advantages over the existing diabetes sensors in the market. This sensor has a linear gas response to acetone from 0.9 ppm to 10 ppm, which leads to accurate detection of acetone concentration in breath of patients with diabetes (usually in the range of 1.7 ppm to 3.7 ppm). This sensor demonstrates high stability, improved selectivity, and high sensitivity for acetone from different gas molecules such as moisture, ethanol, etc. This sensor has a small size that can fit in a pocket. Patients with diabetes can conveniently and discretely carry the sensor for real-time detection of acetone in exhaled breath to recognize human blood glucose level and help determine a patient?s insulin needs.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.